| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Bexarotene | FIMM | pan-cancer | AAC | 1 | 0.0002 |
| mRNA | ZM-447439 | GDSC1000 | pan-cancer | AAC | 0.15 | 0.0003 |
| mRNA | navitoclax:sorafenib (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.14 | 0.0003 |
| mRNA | RAF265 | CCLE | pan-cancer | AAC | 0.19 | 0.0003 |
| mRNA | quizartinib | CTRPv2 | pan-cancer | AAC | 0.15 | 0.0003 |
| mRNA | BRD-K01737880 | CTRPv2 | pan-cancer | AAC | 0.45 | 0.0003 |
| mRNA | TPCA-1 | GDSC1000 | pan-cancer | AAC | 0.12 | 0.0003 |
| mRNA | RDEA119 | FIMM | pan-cancer | AAC | 1.1 | 0.0004 |
| mRNA | Compound 7d-cis | CTRPv2 | pan-cancer | AAC | -0.15 | 0.0005 |
| mRNA | BRD-K55116708 | CTRPv2 | pan-cancer | AAC | 0.14 | 0.0005 |